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In solid tumoursmillions of cells are shed into the blood circulation each day. Only a subset
of these circulating tumour cells (CTCs) survive, many of them presumable because of their
potential to formmulti-cellular clusters also named spheroids. Tumour cells within these
spheroids are protected from anoikis, which allows them to metastasize to distant organs or
re-seed at the primarysite. We used spheroid cultures of head and neck squamous cell car-
cinoma (HNSCC) cell lines as a model for such CTC clusters for determining the role of the
epidermal growth factor receptor (EGFR) in cluster formation ability and cell survival after
detachment from the extra-cellular matrix. The HNSCC cell lines FaDu, SCC-9 and UT-
SCC-9 (UT-SCC-9P) as well as its cetuximab (CTX)-resistant sub-clone (UT-SCC-9R)
were forced to grow in an anchorage-independent manner by coating culture dishes with
the anti-adhesive polymer poly-2-hydroxyethylmethacrylate (poly-HEMA). The extent of
apoptosis, clonogenic survival and EGFR signalling under such culture conditions was eval-
uated. The potential of spheroid formation in suspension culture was found to be positively
correlatedwith the proliferation rate of HNSCC cell lines as well as their basal EGFR
expression levels. CTX and gefitinib blocked, whereas the addition of EGFR ligands pro-
moted anchorage-independent cell survival and spheroid formation. Increased spheroid for-
mation and growth were associated with persistent activation of EGFR and its downstream
signalling component (MAPK/ERK). Importantly, HNSCC cells derived from spheroid cul-
tures retained their clonogenic potential in the absence of cell-matrix contact. Addition of
CTX under these conditions strongly inhibited colony formation in CTX-sensitive cell lines
but not their resistant subclones. Altogether, EGFR activation was identified as crucial factor
for anchorage-independent survival of HNSCC cells. Targeting EGFR in CTC cluster forma-
tion might represent an attractive anti-metastatic treatment approach in HNSCC.
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Introduction
Each day millions of tumour cells are shed into the blood circulation from solid tumours [1].
Of these cells, only a small subpopulation is able to survive and demonstrates tumour-induc-
ing potential enabling metastastic progression [2,3]. Circulating tumour cells (CTCs) have
been detected in peripheral blood of patients in most epithelial tumour types and were signif-
icantly associated with poor prognosis [4–9]. Previous findings revealed the existence of so-
called CTC clusters or circulatingmicroembolis (CTM) which display an increasedmeta-
static potential compared to solitary CTCs [10,11]. In agreement with this, in vivo spheroids
were shown to be exclusively detectable in blood from patients with metastatic disease in var-
ious histological entities indicative of their role in tumour progression and metastasis [12].
CTC clusters can be built from CTCs alone or are mixed with accessory cells including leuko-
cytes, platelets, endothelial cells or fibroblasts [13–15]. In contrast to solitary CTCs, these
CTC aggregates (e.g. 3 CTCs in advanced NSLCLC) [16] were shown to have an advantage
in the blood circulation in terms of protection from an immune attack and anoikis (apoptosis
resulting from loss of cell–cell and cell–matrix contact) [14,17]. Identification of the molecu-
lar mechanisms underlying the CTC cluster formation ability and their maintenance in the
blood circulation may lead to a better understanding of the mechanisms involved in the met-
astatic potential of CTCs and might identify novel therapeutic targets for anti-metastatic
treatment.
In the seminal study of Jost and coworkers, EGFR activation was identified as key factor
for anchorage-independent cell survival of primary and immortalized human keratinocytes
[18]. Subsequent studies demonstrated this function of EGFR in different epithelial tumour
models as well [19–21]. EGFR is overexpressed in many tumours of epithelial origin includ-
ing HNSCC showing upregulated expression in about 90% of patients [22]. Increased levels
of EGFR expression and activation have been associated with poor prognosis, distant metas-
tasis, and therapy resistance [23]. We have previously shown in a breast xenograft model that
EGFR as well as mesenchymal markers are upregulated in the CTC fraction [24]. Addition-
ally, in HNSCC patients with locally advanced disease, we have detected EGFR in the total
fraction of CTCs and its phosphorylated form in more than 50% of CTCs [25]. However, the
causative role of EGFR and its downstream signalling pathway for anchorage-independent
cell survival of CTCs in HNSCC remains unresolved. Previous studies established the forced
suspension culture as a near-physiological in-vitro model in which the tumour spheroids
rather than cells cultured in monolayers mimic biological properties of micrometastases/
CTC clusters, including their architecture as well as morphological and physiological charac-
teristics [26]. In the current study, we used the spheroid model mimicking the conditions
of these CTC clusters and anchorage-independent growth to evaluate whether signalling




Cetuximab (CTX) was provided by Merck Serono (Darmstadt, Germany) and unless other-
wise indicated CTXwas used at a concentration of 100μg/ml. Recombinant epidermal
growth factor (EGF) and amphiregulin (AREG) were purchased from Invitrogen (Carlsbad,
CA, USA). These reagents were used at a concentration of 100ng/ml (EGF, AREG). Gefitinib
was purchased from SelleckChem (Houston, Tx, USA) and used at a concentration of
100nm.
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monolayer; MTT, Methylthiazolyldiphenyl-tetrazolium
bromide; NSCLC, non-small cell lung cancer;
pEGFR, phospho-EGFR; PI, Propidium iodid; poly-
HEMA, Poly(2-hydroxyethyl methacrylate); SCLC,
small cell lung cancer; SD, standard deviation.
Cell Lines
The previously established HNSCC cell lines UT (University of Turku)-SCC-9 (UT-SCC-9)
and SCC-9 cells were kindly provided by T.K. Hoffmann (University of Essen, Dept. of Otorhi-
nolaryngology).The FaDu cell line was purchased from ATCC (Cat. No: ATCC1 HTB-43™).
The identity of the cell lines was confirmed by high-throughput SNP-based authentication
(Multiplexion, Heidelberg, Germany). CTX-resistant subclone of UT-SCC-9 (UT-SCC-9R)
was established by chronic treatment of UT-SCC-9P cells with increasing concentrations of
CTX from 50μg/ml up to 200μg/ml over a period of 7 months. The resistance of treated cells
was validated by performing clonogenic assays (S1 Fig). In addition, UT-SCC-9R was verified
to originate from the UT-SCC-9P by next-generation sequencing in our lab. Cells were cul-
tured in MEM supplemented with 10% fetal calf serum (FCS) and incubated in a humidified
atmosphere of 95% air / 5% CO2 at 37°C. All cell lines were routinely tested for mycoplasma
contamination.
Spheroid Cell Culture
Non-adhesive tissue culture plates were used for forced suspension culture. Briefly, the anti-
adhesive polymer poly-HEMA (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in
ethanol to a final concentration of 10mg/ml and used for coating tissue culture plates. The eth-
anol was evaporated overnight at room temperature and plates were sterilized under UV light
for 2h. Thereafter, cells were plated into pre-coated dishes in serum-freemedium unless stated
otherwise. For assessment of the spheroid formation capacity, HNSCC cells were seeded at a
density of 2,500 cells/well in non-adhesive 96-well plates. After 96h, the total number of spher-
oids per well was determined under light microscope.
For analysis of the effects of EGFR stimulation or blockade on spheroid volume, HNSCC
cells were seeded at a density of 300,000 cells in non-adhesive 6-well plates. Cells were left
untreated or were treated with AREG, EGF, CTX or gefitinib. After an incubation of 72h at
least two microscopic images were taken of each culture well from the areas with highest spher-
oid density. To calculate the mean spheroid volume short and long diameters of 15 spheroids
per sample were measured by the software Image J [27]. Spheroid volumes were then calculated
according to the formula V = a×b2×π/6, with a and b representing the lesser and greater spher-
oid diameters, respectively. Relative spheroid volumes were calculated by setting volumes of
non-treated spheroids to 100%.
Clonogenic Survival Assay
To analyse clonogenic survival following the culture of HNSCC cells in forced suspension,
spheroids were disaggregated to single cells by 10-min treatment with trypsin (0.25%)/EDTA.
Thereafter, cells were plated into 12-well plates at a density of 250 cells per well and incubated
until colonies were formed. Colonies containing 50 cells or more were counted. Plating effi-
ciency and survival fractions for given treatments were calculated on the basis of survival of
non-treated cells. All samples were done in triplicates and at least three independent experi-
ments were carried out.
Proliferation Assay
The growth kinetics of HNSCC cells was determined by cell counting. To this aim, 2×104cells/
well were plated into 12-well culture plates in MEM containing 10% FCS. On days 1, 2, 3 and
4, cells were harvested by trypsinisation and counted in the haemocytometer under the light
microscope.
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Apoptosis Assay
For the detection of apoptotic cells, samples from the volume measurements were harvested by
trypsinisation and analysis of apoptosis was performed by propidium iodide (PI) staining fol-
lowed by flow cytometric analysis as describedby Riccardi and Nicoletti [28]. Briefly, cells were
fixed by 70% (v/v) cold ethanol and stored overnight at -20°C. Fixed cells were washed with
PBS and stained using DNA staining solution (20μg of PI in 1 ml of PBS containing 2mg of
RNase). Subsequently, the fraction of cells with a DNA content less than 2n ("sub-G1 cells") as
a result of apoptotic DNA fragmentation was determined using a FACSCanto II cytometer
(BD Biosciences Europe, Heidelberg, Germany). For each sample 10,000 events were recorded.
Data analysis was performedwith BD FACSDiva Software v6 (BD Biosciences).
MTTCell Viability Assay
Cells were seeded in coated or non-coated 96-well plates at the optimal cell concentration for
each cell line (10,000–75,000 cells (forced suspension); 2,500 cells (monolayer)). Cells were
then left untreated or were treated with AREG, EGF, CTX or gefitinib. Seventy-two hours after
seeding, the MTT reagent (5mg/ml) was added and cells were incubated overnight. After addi-
tion of DMSO, absorbance at 540nm was measured by the use of the AR 2001 microplate
reader (Anthos Mikrosysteme GmbH, Krefeld, Germany). The relative cell viability was calcu-
lated using untreated cells as control.
Western Blotting
Expression levels of phosphorylated-MAPK/ERK (42/44 kDa) were assessed by Western blot-
ting. Cells were treated as indicated in the figure legends. After treatment, cells were lysed with
RIPA buffer (Thermo Scientific, Schwerte, Germany) and protein concentrations were mea-
sured. Thereafter, proteins were electrophoretically separated by SDS-PAGE and transferred to
PVDFmembranes (BioRad,Munich, Germany). Membranes were incubated with the specific
antibodies for pERK1/2 followed by incubation with a secondary antibody conjugated to horse-
radish peroxidase (Cell Signalling Technology, Danvers, MA, USA). Immuno reactive proteins
were visualized using enhanced chemiluminescence (WesternSure1 PREMIUMChemilumi-
nescent Substrate, LI-COR, Bad Homburg, Germany) and the C-Digit Blot scanner (LI-COR,
Bad Homburg, Germany). For loading control an antibody against vinculin (124 kDa; Abcam,
Cambridge, UK) was used.
Statistical Analysis
For assessment of the effects of EGFR stimulation and EGFR blockade on spheroid formation
capacity, apoptosis, proliferation and clonogenic survival, the paired Student`s t-test was used.
The level of significancewas set at p< 0,05. Statistical analyses were carried out using the SPSS
Statistics software (version 22.0.0, IBM, Armonk, NY, USA).
Results
The Extent of Spheroid Formation is Cell Line-Dependent
Since established HNSCC cell lines can show different properties in cell growth and invasive-
ness, we first assessed the extent of spheroid formation in forced suspension in relation to the
growth rates of HNSCC cell lines in monolayer cultures. In the four HNSCC cell lines tested,
we observed formation of spheroids from single-dissociatedHNSCC cells in forced suspension
cultures. As depicted in Fig 1A, FaDu cells showed the highest and SCC-9 cells the lowest
potential to form spheroids, whereas no significant difference was observed in UT-SCC-9P
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cells compared to their cetuximab-resistant subclone UT-SCC-9R. (Fig 1A) The capability of
HNSCC cells to form spheroids was positively correlated with their growth rates (Fig 1B) and
the basal EGFR expression determined by immunoblotting. (Fig 1C)
Autocrine EGFRSignalling Is Maintained in Spheroid Culture of HNSCC
Cell Lines
Since it was shown that EGFR activity has protective effects on epithelial cells when growing in
absence of matrix interaction, we investigated whether endogenous EGFR signallingwas main-
tained under forced suspension conditions. As readout we used the activation of ERK1/ERK2
as downstream factor of the EGFR signal cascade, by examining its phosphorylation status
(pERK1/2). All four cell lines were cultured either in monolayers or forced suspension.We
used serum-free culture conditions for these experiments to avoid stimulation of EGFR by
potential traces of exogenous EGFR ligands in foetal serum.Cells were harvested after 24h, 48h
and 72h, and immunoblotting was performed.Activation of EGFR signalling was observed
under both culture conditions in all cell lines (Fig 2). However, both the pattern of ERK1/
ERK2 activation and its kinetics differed between the cell lines. Whereas FaDu demonstrated
higher expression levels of pERK1 and pERK2 in forced suspension compared to monolayer
cultures, the other three cell lines showed mainly pERK2 expression irrespectively of the type
of culture condition. Interestingly, cell lines UT-SCC-9R and SCC-9 showed a marked reduc-
tion in pERK1/2 after 72h of spheroid culture. This can be explained by a declined growth and
size of spheroids, which is not observed in the other two cell lines.
Fig 1. Spheroid generation is cell line dependent. (A) 2,500 cells were seeded into 96-well plates (poly-HEMA
coated). After 96h, total number of spheroids per well were counted. (B) 2 ×104cells/well were plated into 12-well
culture plates and at indicated times cells were counted. The data points shown in (A) and (B) represent themean
values ± standard deviation (SD) of three independent experiments. (C) Cells were lysed, and protein samples
were subjected to western blot analysis with specific antibodies against EGFR.GAPDHwas used as a loading
control.
doi:10.1371/journal.pone.0163149.g001
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Spheroid Formation Is EGFR-Dependent
To further explore the influence of EGFR signalling on the potential of HNSCC cells to escape
anoikis and to survive in forced suspension, the four cell lines were either treated with EGFR
ligands (100ng/ml AREG or EGF), the EGFR-blocking antibody cetuximab (CTX, 100μg/ml)
or the EGFR-specific tyrosine-kinase inhibitor gefitinib, for 72h. Subsequently, the volume of
formed spheroids was determined. In Fig 3, representative microscopic images from one of
four independent experiments and from each cell line after activation or blockade of EGFR are
shown. Especially in the cetuximab sensitive cell lines, an effect of either EGFR stimulation or
EGFR blockade was observed. In Fig 4, the results from the quantitative analysis of volume
measurements from four independent experiments are presented. For a better comparison of
treatment effects, relative spheroid volumes were calculated in each experiment. Stimulation of
cells cultured under non-adhesive conditions especially with EGF significantly increased spher-
oid volumes in the three CTX-sensitiveHNSCC cell lines compared to their controls. Con-
versely, blocking of EGFR by CTX caused a markedly reduction of spheroid volumes in all cell
lines. The effects of EGFR activation/blockadewas more pronounced in FaDu and SCC-9 com-
pared to UT-SCC-9P and UT-SCC-9R cells. Comparable effects were observedusing gefitinib
for EGFR blockade (Fig 4).
EGFRActivation Has Protective Effects against Anoikis
We next evaluated whether cell survival of HNSCC cells in spheroids was also controlled by
EGFR. For this purpose, all four cell lines were seeded and treated with AREG, EGF, CTX or
gefitinib for 72h in forced suspension or monolayer cultures. In all three CTX-sensitive cell
lines, reduced apoptosis was observed in EGFR ligand-treated compared to untreated cells (Fig
Fig 2. Autocrine EGFR signalling is maintained in spheroid culture of HNSCC cell lines.Cells were cultured
as monolayer (M) or spheroids (FS) for 24h, 48h or 72h in serum-freemedium. The expression levels of pERK1/2
(42/44 kDa) and vinculin (internal loading control; 124 kDa) were analysed by immunoblotting. The values of the
quantitative analysis are depicted as pERK1/2 protein levels relative to vinculin expression levels.
doi:10.1371/journal.pone.0163149.g002
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5). Although EGFR activation/blockade showed similar effects in forced suspension and mono-
layer cultures, the most prominent reduction or increase in apoptosis was observed in spheroid
cultures, indicative for a stronger dependence of cells on EGFR signalling under the former
culture conditions. Especially the cell line SCC-9 with the lowest capability to form spheroids
demonstrated the strongest rescue in forced suspension culture after stimulation by EGF. Sur-
prisingly, the monolayer showed reverse effects in this cell line. No significant changes were
observed in UT-SCC-9R cells (Fig 5). These results were verified usingMTT assays. (Fig 6) Cor-
roborating the results from the analysis of apoptosis, a strong protective effect of EGFR stimula-
tion in FaDu and SCC-9 cells cultured in forced suspension was observed. In UT-SCC-9P cells
only slight effects of EGFR stimulation but clear effects of EGFR blockadewere detected. In
UT-SCC-9R cells EGFR stimulation or inhibition did not affect cell proliferation (Fig 6).
Clonogenic Potential of HNSCC Spheroids Is Conserved by EGFR
Activation during Forced Suspension Culture
During their journey through hematogenous routes, small CTC clusters need to maintain their
clonogenic potential for establishment of new lesions at distant organs. We therefore deter-
mined whether EGFR stimulation during forced suspension culture would also conserve the
clonogenic potential of spheroid-derivedHNSCC cells. Clonogenic survival assays were per-
formed using cells which had been cultured for 72h either in monolayers or forced suspension
in the absence or presence of EGFR ligands or CTX.Overall, clonogenic survival potential was
slightly higher in cells derived frommonolayer compared to forced suspension cultures. (Fig 7)
Addition of AREG and EGF during forced suspension culture improved clonogenic survival of
CTX-sensitive cells, which was more pronounced after stimulation with EGF compared to
AREG.While the effect of EGF stimulation on clonogenic survival was significant for SCC-9
and UT-SCC-9P cells, only a trend was observed for FaDu. Conversely, CTX significantly
Fig 3. Effects of EGFR activation/blockade on spheroid formation.Cells were seeded at a density of 300,000
cells/well into 6-well plates and cultured under non-adherent conditions in the absence or presence of EGFR
ligands (AREG, EGF) or EGFR blocking agents (CTX, gefitinib). Pictures were taken 72h after cell seeding. (5x
magnification)
doi:10.1371/journal.pone.0163149.g003
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blocked clonogenic survival in all CTX-sensitive cells. The inhibitory effect was more pro-
nounced in spheroid compared to monolayer cultures. As seen also for apoptosis, there was no
influence of EGF or CTX on the clonogenic potential of CTX-resistant UT-SCC-9R cells.
Discussion
Using spheroid culture of HNSCC cell lines as a representative in-vitro model for CTC cluster
formation and growth after loss of cell-matrix interactions contributing to the metastatic
spread in vivo, [10] we here established an important role of EGFR activation for HNSCC cell
survival and spheroid maintenance under such conditions. Spheroid formation leading to resis-
tance to anoikis by autocrine EGFR stimulation could bemediated by the activation of different
downstream components of the EGFR signalling pathway including upregulation of the hyp-
oxia-inducible-factor-1 (HIF1) [29] or activation of the PI3K/AKT [30] as well as the MAPK
pathway [18]. In support of a major role of MAPK, the activation of this pathway was shown to
be required for spheroid formation [18]. Consistent with these previous studies, we observed
that autocrine EGFR signalling throughMAPK/ERKwas maintained after loss of cell adher-
ence in all HNSCC cells and that the strongest activation of MAPK/ERKwas observed in the
cell line with the highest capacity of spheroid formation. Moreover, exogenous stimulation of
EGFR increased the number and volume of spheroids. Interestingly, differences in the effects
of AREG and EGF on spheroid formation capacity were observed, indicating divergent molec-
ular mechanisms influenced by these two EGFR ligands. In line with our observation, EGF was
demonstrated to induce morphological changes in colon cancer cell lines whereas AREG had
an effect only on cell proliferation [31].
Fig 4. Effects of EGFR activation/blockade on spheroid volume.Cells were seeded at a density of 300,000
cells/well into poly-HEMA coated 6-well plates and treatedwith the indicated agents. After 72h, the diameters of at
least 15 spheroidswere measured and spheroid volumes calculated relative to the untreated spheroids. Bars
represent mean values ± SD of four independent experiments. For the cell line SCC-9 the y-axis was adapted due
to the EGF-inducedstrong increase in spheroid volumes.
doi:10.1371/journal.pone.0163149.g004
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The results from our in-vitro model are suggestive of EGFR being a master regulator of cell
survival not only in the bulk tumour [32] but also in CTC-forming clusters. This conclusion is
further supported by our previous observation that basal expression of EGFR can be detected
in 100% and activated EGFR (pEGFR) in 55% of CTCs from HNSCC patients with locally
advanced stage disease [25]. EGFR-expressing CTCs have also been detected in metastatic
breast cancer patients as well as patients with non-small-cell lung cancers [33,34]. These data
strongly suggest that EGFRmight not only represent an attractive molecular target in the bulk
tumour [35] but also in CTCs to prevent them from forming clusters. In favor of such a thera-
peutic approach is our previous observation that the radiation-induced increase in CTC num-
bers was less pronounced when radiotherapy was combined with CTX compared to
chemotherapy [25]. However, addition of CTX to radiotherapy significantly improved local
but not distant control in the Bonner trial [36]. This negative result could be explained by an
enrichment of cells with primary or acquired resistance to CTX among CTCs. Generally, in pri-
mary tumours acquired resistance to anti-EGFR antibodies could result from compensatory
mechanisms for reduced EGFR signaling [37] as well as genetic alterations in the EGFR-RAS--
RAF-MEK signaling pathway or other receptor tyrosine kinases [38]. Several previous studies
also revealed the hepatocyte growth factor receptor MET as a potential mediator of resistance
to anti-EGFR targeted therapies [39–43]. MET activates intracellular signaling cascades includ-
ing RAS-MAPK and PI3K-AKT pathways, NF-κB andWnt/GSK-3β/β-Catenin signaling [44].
Moreover, an increased expression of MET in combination with CD47 and EpCAM was
shown to be correlated with a high tumorigenicity of CTC subpopulations [2,45]. Increased
Fig 5. Activationof EGFR protectsHNSCC cells against anoikis.Cells were seeded at a density of 300,000
cells/well in non-coatedor poly-HEMAcoated 6-well plates and were immediately treatedwith either EGFR ligands
or blocking reagents. After 72h, cells frommonolayer (M) and forced suspension (FS) cultureswere harvested and
the apoptotic fraction was determined by PI staining and subsequent flow cytometry. Bars represent the mean
percentages of apoptotic cells ± SD of at least three independent experiments. Significant changes compared to
control aremarkedwith an asterisk.
doi:10.1371/journal.pone.0163149.g005
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expression of MET has been described for CSCs and has a key role in cell growth, survival and
metastasis [44]. Therefore, CTCs could contain a subpopulation of CSCs with intrinsically
lower sensitivity to CTX treatment. CSC characteristics have indeed been described for CTCs,
and it was postulated that it is their stemness feature which enables them to survive in periph-
eral blood as single-dissociated cells or small spheroids [46–48] (reviewed in ref. 4). Thus, tar-
geting also key regulators in MET activated pathways might help improving distant control in
HNSCC. These aspects are currently under investigation in our laboratory.
The poor distant control by CTX treatment in HNSCC patients might be alternatively
explained by the occurrenceof CTCs in peripheral blood of patients as tightly packed spheroids
[12]. Thus, resistance to CTX could simply result from a reduced accessibility of the antibody
to inner spheroid layers where the truemetastasis-initiating cells might be located. Recently,
the in-depth characterization of tumour cell spheroids from peripheral blood of patients with
solid cancers revealed heterogeneous cell layers, with cells displaying a cancer stem cell (CSC)-
like phenotype in the center and cells with a more differentiated phenotype at the spheroid sur-
face [12]. Moreover, in CSCs high expression of efflux pump genes is known to cause multi-
drug resistance, especially for chemotherapeutic agents [49,50]. In agreement with this,
another study demonstrated resistance to anoikis and cytotoxic drugs for CTM rather than for
solitary CTCs in SCLC [17]. If confirmed in our in-vitro model, strategies to target the mecha-
nisms involved in spheroid aggregation and maintenance might represent an attractive combi-
natory approach to improve the anti-metastatic efficacy of EGFR blockade as well as
chemotherapy in CTC clusters.
Fig 6. CTX affects proliferation of spheroids in sensitivecell lines.MTT assays were performed in 96-well
plates with cells treatedwith EGFR stimulating or blocking reagents in monolayer (M) or forced suspension (FS)
culture. Bars represent mean percentages± SD of four independent experiments. Significant changes compared to
control aremarkedwith an asterisk.
doi:10.1371/journal.pone.0163149.g006
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In conclusion, HNSCC cells lacking cell-matrix interactions require mechanisms including
EGFR signalling to form cell clusters to be protected from anoikis-like cell death. An anti-meta-
static therapeutic approach directed against CTCs or CTC clusters should thus include EGFR
as a molecular target. However, other mechanisms such as the factors responsible for cell
aggregation in tightly packed spheroids and/or the acquisition of a CSC phenotype in such
structuresmight also contribute to resistance from anoikis. Future studies focusing on a more
detailed characterisation of the architecture and physiological characteristics of spheroids in
vitro and in vivo are required in order to optimize current treatment concepts for a better dis-
tant tumour control in HNSCC.
Supporting Information
S1 Fig. Validation of resistance and sensitivity to cetuximab in different HNSCC cell lines.
UT-SCC-9P was chronically treated with increasing cetuximab concentrations. The CTX-resis-
tant phenotype of the subclone UT-SCC-9R was confirmed by assessment of the inhibitory
effect of CTX treatment on clonogenic cell survival in UT-SCC-9R compared to the parental
cell line UT-SCC-9P, FaDu and SCC-9. Bars show the mean survival fractions (SF) ± standard
Fig 7. EGFR signalling regulates clonogenic survival of HNSCC cells derived from forced suspension
cultures.Cells were cultured as monolayer (M) or in forced suspension (FS) in the absence or presence of EGF,
AREG or CTX. 72h later, cells were harvested, disaggregated to single cells and subjected to clonogenic survival
analysis. Bars represent the surviving fractions (SF) ± SD from three independent experiments. Significant
changes compared to control are markedwith an asterisk.
doi:10.1371/journal.pone.0163149.g007
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